share_log

CellProthera, BioCardia Report Success From Collaborative Phase II Trial Of ProtheraCytes For Acute Myocardial Infarction; Plan To Continue Relationship Into Phase III

Benzinga ·  Jul 8 07:05

CellProthera's clinical results from the Phase I/IIb EXCELLENT Trial, which studied the feasibility of transendocardial injection of ProtheraCytes for acute myocardial infarction when delivered in combination with the standard of care, suggested an effective solution for preventing heart failure progression in the patients at high risk following a heart attack.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment